Business
InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares
JENA, Germany, April 12, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing
About this update from Inflarx N.v.
[{"type":"text","content":"JENA, Germany, April 12, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the pricing of its underwritten public offering of 9,411,765 ordinary shares at an offering price of $4.25 per ordinary share. The offering is expected to close on April 14, 2023, subject to the satisfaction of customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to 1,411,764 additional ordinary shares at the public offering price, less the underwriting discount. The Company intends to use the net proceeds from the offering to fund the continued development of vilobelimab, general research and development expenses and investments in the Company’s commercial infrastructure and for working capital and general corporate purposes. Raymond James & Associates, Inc. is serving as sole book-running manager for the offering, and LifeSci Capital, LLC as co-manager. A shelf registration statement relating to the securities being sold in this offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on July 17, 2020. The offering will be made only by means of a prospectus and prospectus supplement. The prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available at the SEC’s website located at www.sec.gov. When available, copies of the prospectus supplement and accompanying prospectus related to the offering may be obtained by contacting Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by email at [email protected]. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About InflaRx N.V.: InflaRx GmbH (in Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together “InflaRx”). InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmace...